SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech News
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: tom pope7/1/2011 10:25:33 PM
   of 7143
 
Triage is not yet alive and well. It will be when the arithmetic catches up.. Provenge also got a pass, but that one is more understandable, perhaps.

Updated: Medicare will continue to pay for the drug Avastin as a treatment for breast cancer even if the Food and Drug Administration revokes the drug’s approval as a treatment for that disease, a Medicare spokesman said on Thursday.

“The label change will not affect our coverage,’’ Don McLeod, a spokesman for the Centers for Medicare and Medicaid Services, said.

The statement could allay concerns of women who think the drug is helping them but fear insurers would stop paying for it the F.D.A. rules that it is no longer appropriate as a treatment for metastatic breast cancer.

An advisory committee to the agency voted unanimously Wednesday in favor of rescinding the breast cancer approval, saying the latest evidence suggests the drug is not effective. The final decision will be made by the F.D.A. commissioner, Dr. Margaret A. Hamburg, some time after a public comment period ends on July 28.<snip>
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News